The nicotine transdermal system

Clinics in Dermatology

Volumn 16, Issue 5, 1998, Pages 599-615

  Gore, Anuradha V ^a   Chien, Yie W ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b Controlled Drug Delivery Res Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

ARTICLE; BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; PRIORITY JOURNAL; SMOKING CESSATION; SUBSTANCE ABUSE; TRANSDERMAL DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0032157988     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(98)00046-7     Document Type: Review

References (105)

1. 1. Haxby DG. Treatment of nicotine dependence. Am J Health Syst Pharm 1995;52:265-81.
2. 2. McGinnis JM, Foege WH. Actual cases of death in the United States. JAMA 1993;270:2207-12.
3. 3. Centers for Disease Control and Prevention. Cigarette smoking - attributable mortality and years of potential life lost - United States, 1990. MMWR 1993;42:645-9.
4. 4. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 1992 - and changes in current definition of cigarette smoking. MMWR 1994;43:342-6.
5. 5. Telepchak JM. Smoking cessation: New strategies and opportunities for pharmacists. Am Druggist 1997;January:48-51.
6. 6. Pierce JP, Giplin E, Farkas AJ. Nicotine patch use in the general population: Results from the 1993 California tobacco survey. J Natl Cancer Inst 1992;87:87-93.
7. 7. Gora ML. Nicotine transdermal systems. Ann Pharmacother 1993;27:742-50.
8. 8. Peters JA. Nicotine replacement therapy in cessation of smoking. Mayo Clin Proc 1990;65:1619-23.
9. 9. Prignot J. Pharmacological approach to smoking cessation. Eur Respir J 1989;2:550-60.
10. 10. Chien YW. Recent advances in noninvasive systemic delivery of pharmaceuticals and biopharmaceuticals. Drug Dev Ind Pharm 1994;20:417-68.
11. 11. Centers for Disease Control. The health consequences of smoking. Nicotine addiction. A report from the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Center for Health Promotion and Education, Office on Smoking and Health. Rockville, MD: U.S. Government Printing Office, 1998 (223-672/0).
12. 12. Wesnes K, Warburton DM. Smoking, nicotine and human performance. Pharmacol Ther 1983;21:189-208.
13. 13. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988;319:1318-30.
14. 14. Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 1983;19:989-92.
15. 15. Fagerstrom KO. Tolerance, withdrawal and dependence on tobacco and smoking termination. Int Rev Appl Psychol 1983;32:29-52.
16. 16. West RJ. Psychology and pharmacology in cigarette withdrawal. J Psychosom Res 1984;28:379-86.
17. 17. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996;36:597-613.
18. 18. Chien YW, editor. Transdermal drug delivery and delivery systems: Novel drug delivery systems. 2nd ed. New York: Marcel Dekker, 1992:301-80.
19. 19. Nicoderm® (Nicotine transdermal system) product information. Marion Merrell Dow; 1991.
20. 20. Habitrol® (Nicotine transdermal system) product information. Ciba-Geigy; 1992.
21. 21. Nicotrol® (Nicotine transdermal system) product information. Parke-Davis; 1992.
22. 22. Glover ED. Transdermal nicotine patch for smoking cessation (Letter). N Engl J Med 1992;326:344.
23. 23. ProStep® (Nicotine transdermal system) product information. Lederle; 1992.
24. 24. Ho H, Chien YW. Kinetic evaluation of transdermal nicotine delivery systems. Drug Devel Ind Pharm 1993; 19:295-313.
25. 25. FDA review of NDA on Nicoderm®. Submitted by Maion Merrell Dow (1991).
26. 26. Berner B. Pharmacokinetics of skin penetration. In: Koydonieus A.F., Berner B, editors. The transdermal delivery of drugs, vol 2. New York: Marcel Dekker, 1992:1-35.
27. 27. Ross HD, Chan KKH, Piraino AJ, et al. Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. Pharmacol Res 1991;8:385-8.
28. 28. Dubois JP, Sioufi A, Muller P, et al. Phamacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems. Methods Find Exp Clin Pharmacol 1989;11:187-95.
29. 29. Berner B, John VA. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinet 1994; 26:121-34.
30. 30. Benowitz NL, Chan K, Denaro CP, et al. Stable isotope method for studying transdermal drug absorption: The nicotine patch. Clin Pharmacol Ther 1991;50:286-93.
31. 31. Gupta SK, Okerholm RA, Eller M, et al. Comparison of the pharmacokinetics of two nicotine transdermal systems: Nicoderm and Habitrol. J Clin Pharmacol 1995;35:493-8.
32. 32. FDA review of NDA for Nicotrol®. Kabi Pharmacia; 1992.
33. 33. Wester RC, Maibach HI. Percutaneous absorption of drugs. Clin Pharmacokinet 1992;23:253-66.
34. 34. Gorsline J, Okerholm RA, Rolf CN, et al. Comparison of plasma nicotine concentrations after application of Nicoderm (transdermal nicotine system) to different skin sites. J Clin Pharmacol 1992;32:576-81.
35. 35. Devane J, Mulligan S, Martin M. Comparative delivery of nicotine from alternative transdermal sites of application (Abstract). Pharmacol Res 1989;6:S232.
36. 36. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
37. 37. Sachs DP, Sawe U, Leishow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group therapy. Arch Intern Med 1993; 153:1881-90.
38. 38. Gourlay SG, Benowitz NL. The benefits of stopping smoking and role of nicotine replacement therapy in older patients. Drugs Aging 1996;9:8-23.
39. 39. Barkve TF, Langseth-Manrique K, Bredesen JE, et al. Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature. Am Heart J 1986;112:537-41.
40. 40. Kukkonen-Harjula K, Oja P, Laustiola K, et al. Hemodynamic and hormonal responses to heat exposure in a Finnish sauna bath. Eur J Appl Physiol 1989;248: 345-9.
41. 41. Vanakoski J, Seppala T, Sievi E, et al. Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine. Clin Pharmacol Ther 1996;60:308-15.
42. 42. Klemsdal TO, Gjesdal K, Zahlsen K. Physical exercise increases plasma concentrations of nicotine during treatment with nicotine patch. Br J Clin Pharmacol 1995;39:677-9.
43. 43. Russell MAH, Jarvis MJ, Feyerabend C, et al. Nasal nicotine solution: A potential aid to giving up smoking. BMJ 1983;286:683-4.
44. 44. Sneider NG, Lunell E, Olmstead RE, et al. Clinical pharmacokinetics of nasal nicotine delivery. Clin Pharmacokinet 1996;31:65-80.
45. 45. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994;308:21-6.
46. 46. Gupta SK, Hwang SS, Causey D, et al. Comparison of nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) and half-hourly smoking. J Clin Pharmacol 1995;35:985-9.
47. 47. West RJ, Jarvis MJ, Phil M, et al. Plasma nicotine concentrations from repeated doses of nasal nicotine solution. Br J Addiction 1984;79:443-5.
48. 48. Benowitz NL, Jacob P III, Fong I, et al. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268: 296-303.
49. 49. Keller-Stanislawski B, Caspary S, Merz PG, et al. Transdermal nicotine substitution: Pharmacokinetics of nicotine and cotinine. Int'l J Clin Pharmacol Ther Tox 1993; 31:417-21.
50. 50. Benowitz NL. Clinical pharmacology of nicotine. Annu Rev Med 1986;37:21-32.
51. 51. Specter R, Goldberg MJ. Active transport of nicotine by isolated choroid plexus in vitro. J Neurochem 1982;38: 594-6.
52. 52. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an aid to smoking cessation. Drugs 1992;44:498-529.
53. 53. Rose JE, Jarvik ME, Rose KD. Transdermal administration of nicotine. Drug Alcohol Depend 1984;13:209-13.
54. 54. Stein PK, Rottman JN, Keiger RE. Effect of 21-mg transdermal nicotine patches and smoking cessation on heart rate variability. Am J Cardiol 1996;77:701-5.
55. 55. Muller P, Imhof PR, Mauli D, et al. Human pharmacological investigations of a transdermal nicotine system. Methods Find Exp Clin Pharmacol 1989;11:197-204.
56. 56. Benowitz NL, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988;44:23-8.
57. 57. Benowitz NL, Jacob P III, Jones RT, et al. Inter-individual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982;221:368-72.
58. 58. Waeber B, Schaller MD, Nussberger J, et al. Skin blood flow reduction induced by cigarette smoking: Role of vassopressin. Am J Physiol 1984;247:H895-H901.
59. 59. Burn GP, Singh R. The antidiuretic response and excretion of pituitary (posterior lobe) extract in man, with reference to action of nicotine. Br J Pharmacol 1951;6: 471-82.
60. 60. Rowe JW, Kilgore A, Robertson GL. Evidence in man that cigarette smoking induces vassopressin release via airway-specific mechanism. J Clin Endocrinol Metab 1980;51:170-2.
61. 61. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995;155:1933-41.
62. 62. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994;308:21-6.
63. 63. Dickersin K, Berlin JA. Meta-analysis: State of the science. Epidemiol Rev 1992;14:154-76.
64. 64. Mosteller F, Chalmers TC. Some progress and problems in meta-analysis of clinical trials. Stat Sci 1992;7:227-36.
65. 65. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: A meta-analysis. JAMA 1994;271:1940-7.
66. 66. Cepada-Benito A. A meta-analytical review of the nicotine chewing gum. J Consult Clin Psychol 1993;61:751-60.
67. 67. Fiore MC, Novotny TE, Pierce JP, et al. Methods used to quit smoking in the United States: Do cessation programs help? JAMA 1990;263:2760-5.
68. 68. Orleans CT. Treating nicotine dependence in medical settings: A stepped-care model. In: Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford University Press, 1993:145-61.
69. 69. Silagy C, Manta D, Fowler G, et al. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139-42.
70. 70. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation: A randomized trial with telephone counseling. Arch Intern Med 1993;153:1917-23.
71. 71. Jorenby DE, Smith SS, Fiore M, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995;274:1347-52.
72. 72. Abelin T, Buehler A, Muller P, et al. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989;1:7-10.
73. 73. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: Six-month results from two multi-center controlled clinical trials. JAMA 1991; 35:366-80.
74. 74. Fagerstrom KO, Lunell E, Molander LM. Continuous and intermittent transdermal delivery of nicotine: Blockade of withdrawal symptoms and side effects. J Smoking Related Dis 1991;2:173-80.
75. 75. Rose-JE, Levin ED, Behm FM, et al. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther 1990; 47:323-30.
76. 76. Hurt RD, Dale LC, Fredricson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. JAMA 1994;271:595-600.
77. 77. Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy: Percentage of replacement and smoking cessation. JAMA 1995;247:1353-58.
78. 78. Pickworh WB, Fant RV, Butschky MF, et al. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther 1996;279:450-6.
79. 79. Minnekar E, Buchkremer G, Block M. The effect of different dosages of a transdermal nicotine substitution system on the success rate of smoking cessation therapy. Methods Find Exp Clin Pharmacol 1989;11:219-22.
80. 80. Tonnesen P, Norregaard J, Simonsen K, et al. A double blind trial of 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991;325:311-5.
81. 81. Abelin TH, Ehrsam R, Buhler-Reichert A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol 1989;11:205-14.
82. 82. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-1203.
83. 83. Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation: Who will quit with and without the nicotine patch? JAMA 1994;271:589-94.
84. 84. Yudkin PL, Jones L, Lancaster T, et al. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Br J Gen Pract 1996;46:145-8.
85. 85. Paoletti P, Fornai E, Maggiorelli F, et al. Importance of baseline cotinine plasma values in smoking cessation: Results from a double-blind study with nicotine patch. Eur Respir J 1996;9:643-51.
86. 86. Fagerstorm KO, Sneider NG, Lunell E. Effectiveness of nicotine patch and gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993;111:271-7.
87. 87. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch Intern Med 1991;151:749-52.
88. 88. Buchkremer G, Bents H, Horstmann M, Opitz K. Combination of behavioral smoking cessation therapy with transdermal nicotine substitution: Long-term effects. Excerpta Medica 1988;780:857-60.
89. 89. Echelberg D, Stolze P, Block M, et al. Contact allergies inducted by TTS-treatment. Methods Find Exp Clin Pharmacol 1989;11:223-5.
90. 90. Woolf A, Burkhart K, Caraccio T, et al. Self-poisoning among adults using multiple transdermal nicotine patches. Clin Toxicol 1996;34:691-8.
91. 91. Erwin J, Britten N, Jones R. General practitioners' views on over-the-counter sales by community pharmacists. BMJ 1996;312:617-8.
92. 92. Snyder K. More Rx drugs ready to make the big switch. Drug Topics 1995;139 (November):60.
93. 93. Morgan PP, Cohen L. Off the prescription pad and over the counter: The trend toward drug deregulation grows. Can Med Assoc J 1995;152:387-9.
94. 94. Benowitz NL. Nicotine replacement therapy: What has been accomplished - can we do better? Drugs 1993;45: 157-70.
95. 95. Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991;266:3174-7.
96. 96. Benrimoj SI, Langford JH, Bowden MG, et al. Switching drugs' availability from prescription only to over-the-counter status: Are elderly patients at increased risk? Drugs Aging 1995;7:255-65.
97. 97. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335: 1792-8.
98. 98. Pinney JM. Factors affecting availability of treatment. In: Henningfield JE, Stotzer ML, editors. New developments in nicotine-delivery systems. Ossining, NY: Cortland Communications, 1990:79-87.
99. 99. Orleans CTT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription patch for the elderly - a first look at "real world" patch users. JAMA 1994;271:601-7.
100. 100. Oster G, Delea TE, Huse DM, et al. The benefits and risks of over-the-counter availability of nicotine Polacrilex ("nicotine gum"). Med Care 1996;34:389-402.
101. 101. Glover ED, Byrd RC. OTC nicotine gum (Letter). J Fam Pract 1995;40:15-17.
102. 102. Sonderskov J, Olsen J, Sabroe S, et al. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997; 145:309-18.
103. 103. Belcher M, Jarvis M, Sutherland G. Nicotine absorption and dependence in an over-the-counter aid to stopping smoking. BMJ 1989;298:570-1.
104. 104. Lin S, Ho H, Chien YW. Development of a new nicotine transdermal delivery system: In vitro kinetics studies and clinical pharmacokinetic evaluator in two ethnic groups. J Control Rel 1993;26:175-93.
105. 105. Lin S, Chien YW. Transdermal nicotine delivery systems: Multi-institutional cooperative bioequivalence studies. Drug Dev Ind Pharm 1993;19:2765-93.